# 2026-05322: FDA Targets Blood-Zapping Devices in Cancer Fight

2026-05322, Effective Date of Requirement for Premarket Approval Applications for Blood Irradiators Intended To Prevent Metastasis, is a Federal Register proposed rule from Health and Human Services Department, Food and Drug Administration published 2026-03-18, effective Either electronic or written comments on the proposed order must be submitted by May 18, 2026. FDA intends that, if a final order based on this proposed order is issued, anyone who wishes to market blood irradiators intended for use in the irradiation of intraoperatively salvaged blood for cancer patients undergoing surgery to assist in the prevention of metastasis must submit a PMA prior to the last day of the 30th calendar month beginning after the month in which the classification of the device in class III became effective. See section III for the effective date of any final order that may publish based on this proposed order. See section VI of this document for more information about submitting a PMA.; PRIA reads it as touching household money (as of 2026-06-11).

- Canonical: https://policyrisk.com/federal-register/2026-05322
- As of: 2026-06-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-05322
- Title: Effective Date of Requirement for Premarket Approval Applications for Blood Irradiators Intended To Prevent Metastasis
- Type: Proposed Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 12966
- Published: 2026-03-18
- Effective: Either electronic or written comments on the proposed order must be submitted by May 18, 2026. FDA intends that, if a final order based on this proposed order is issued, anyone who wishes to market blood irradiators intended for use in the irradiation of intraoperatively salvaged blood for cancer patients undergoing surgery to assist in the prevention of metastasis must submit a PMA prior to the last day of the 30th calendar month beginning after the month in which the classification of the device in class III became effective. See section III for the effective date of any final order that may publish based on this proposed order. See section VI of this document for more information about submitting a PMA.
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-11

## In one line

FDA Targets Blood-Zapping Devices in Cancer Fight

## Summary

The FDA is planning to require companies that make blood irradiators used during cancer surgeries to get special approval before selling them. This change helps make sure these devices are safe and effective in preventing cancer spread. If finalized, manufacturers will have about 30 months to submit their approval applications, so they should get ready soon!

## Abstract

The Food and Drug Administration (FDA) is proposing to require the filing of a premarket approval application (PMA) for blood irradiators intended to irradiate intraoperatively salvaged blood for cancer patients undergoing surgery to assist in prevention of metastasis, which are unclassified, preamendments devices. FDA is summarizing its proposed findings regarding the degree of risk of illness or injury designed to be eliminated or reduced by requiring the devices to meet PMA requirements of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the benefits to the public from use of the devices.

## Effects PRIA read

- PMA requirement for blood irradiators: cost, high. If finalized, manufacturers of blood irradiators used to irradiate intraoperatively salvaged blood to help prevent metastasis must file a premarket approval (PMA). The PMA must be filed by the last day of the 30th calendar month after the device is classified into class III.
- Short review window, continued marketing if timely filed: mixed, medium. FDA says it intends to review any PMA for these devices within 180 days. A device that was in commercial distribution before May 28, 1976 (or found substantially equivalent by that date) may remain on the market during FDA's PMA review if a PMA is filed on time.
- Market removal and investigational use rules: cost, high. If a PMA is not timely filed, the device could be deemed adulterated and subject to enforcement, and manufacturers must stop distribution if a PMA is denied. Devices may only be distributed for investigational use under an approved investigational device exemption (IDE).
- PMA must include clinical evidence and testing: cost, high. FDA requires a PMA to include valid scientific evidence, full preclinical and clinical reports, and performance testing showing reasonable assurance of safety and effectiveness. FDA also encourages early meetings via the Q-Submission Program and recommends submitting an IDE at least 30 days before…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-05322 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/18/2026-05322/effective-date-of-requirement-for-premarket-approval-applications-for-blood-irradiators-intended-to)
- [2026-05322 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-18/pdf/2026-05322.pdf)

## Related
- [Previous: 2026-05320, Medical Devices; Radiology Devices; Classification of Blood Irradiators](https://policyrisk.com/federal-register/2026-05320)
- [Next: 2026-05327, Airworthiness Directives; The Boeing Company Airplanes](https://policyrisk.com/federal-register/2026-05327)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-05322 (as of 2026-06-11).
